Entries Are Sought for Kushner Writing Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

BETHESDA, Md--The American Medical Writers Association is seeking applications for the 1996 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer.

BETHESDA, Md--The American Medical Writers Association is seekingapplications for the 1996 Rose Kushner Awards for Writing Achievementin the Field of Breast Cancer.

Categories include articles (newspapers and magazines, or scientificjournals), books (medical and lay), brochures and monographs,and scripts for video, film, or radio (medical and lay audi-ences).The winning entry in each category is awarded $1,000, providedthrough a grant from Zeneca Pharmaceuticals.

Entries must be received by May 10, 1996. For information, writeto the Rose Kushner Award Committee, American Medical WritersAssociation, 9650 Rockville Pike, Bethesda, MD 20814-3998. Phone301-493-0003 or fax 301-493-6384.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content